American Century Companies
TNGX icon

American Century Companies’s Tango Therapeutics TNGX Stock Holding History

American Century Companies’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-65,146
Closed -$89.3K – 2940
2025
Q1 		$89.3K Sell
65,146
-45,302
-41% -$111K ﹤0.01% 2829
2024
Q4 		$341K Buy
110,448
+12,162
+12% +$56.5K ﹤0.01% 2641
2024
Q3 		$757K Buy
98,286
+19,590
+25% +$187K ﹤0.01% 2337
2024
Q2 		$675K Buy
78,696
+219
+0.3% +$1.69K ﹤0.01% 2330
2024
Q1 		$623K Buy
78,477
+8,068
+11% +$86.5K ﹤0.01% 2348
2023
Q4 		$697K Buy
70,409
+46,691
+197% +$405K ﹤0.01% 2227
2023
Q3 		$267K Buy
23,718
+1,826
+8% +$11.1K ﹤0.01% 2491
2023
Q2 		$72.7K Buy
21,892
+523
+2% +$1.88K ﹤0.01% 2729
2023
Q1 		$83.8K Buy
21,369
+2,888
+16% +$16.8K ﹤0.01% 2569
2022
Q4 		$134K Sell
18,481
-27,379
-60% -$193K ﹤0.01% 2413
2022
Q3 		$166K Buy
+45,860
New +$196K ﹤0.01% 2265

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

American Century Companies's TNGX Position: Q2 2025 in Review

American Century Companies sold out of Tango Therapeutics (TNGX) in Q2 2025, closing a stake of 65,146 shares — an estimated $89.3K sold.

American Century Companies first reported a position in TNGX in Q3 2022 and held it in 11 quarters. The position peaked at $757K in Q3 2024. 115 funds tracked by Wall St. Rank hold TNGX as of Q2 2025.

  • American Century Companies reported no remaining Tango Therapeutics position as of Q2 2025 after selling out during the quarter.
  • American Century Companies sold 65,146 Tango Therapeutics shares in Q2 2025, an estimated $89.3K.
  • American Century Companies first reported a position in Tango Therapeutics in Q3 2022 and held it in 11 quarters.
  • American Century Companies's Tango Therapeutics position peaked at $757K in Q3 2024.
  • 115 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2025.

Based on American Century Companies's 13F filing for Q2 2025, filed 12 Aug 2025.